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Abstract
This review summarizes the discussion of a session held during the 2018 North American Cystic 
Fibrosis Conference titled “Challenging Cases in Nontuberculous Mycobacterial (NTM) 
Management”. In this session, a multidisciplinary panel of NTM experts discussed clinical 
challenges related to management of NTM infection in people with CF in which decision-making 
falls outside of the CFF/ECFS NTM guidelines. Topics discussed included managing of newly 
acquired NTM infection, selecting and monitoring treatment regimens, determining treatment 
endpoints, and caring for patients after NTM treatment.
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Respiratory infections with nontuberculous mycobacteria (NTM) affect ~20% of people 
with cystic fibrosis (CF), and have increased in prevalence over the past two decades1. NTM 
infections pose significant challenges for clinical management. The clinical course of NTM 
infection can be highly variable, ranging from transient, self-resolving infection to 
pulmonary disease associated with significant clinical decline, morbidity, and mortality2. 
The nature of NTM treatment regimens further complicates decision-making. Recommended 
NTM treatment consists of at least one year of three or more antibiotics, with associated 
toxicities, costs, and burden of care3.
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To address the clinical challenges of NTM infection in CF, the Cystic Fibrosis Foundation 
(CFF) and the European Cystic Fibrosis Society (ECFS) jointly published guidelines on the 
management of NTM infection in CF in 20163. The CF specific guidelines are built on the 
general guidelines for NTM pulmonary disease published by the American Thoracic Society 
(ATS) and the Infectious Disease Society of America (IDSA) in 20074. The CFF/ECSF 
NTM guidelines provide a framework for the clinical approach to NTM infection in CF, 
including recommendations for NTM infection screening, clinical and microbiologic criteria 
for NTM pulmonary disease diagnosis, suggested treatment regimens, and monitoring 
schedules for drug toxicities.
At the North American CF Conference in 2018, a session titled “Challenging Cases in NTM 
Management” highlighted clinical scenarios in which decision making falls outside of the 
published NTM guidelines. The session consisted of an interactive discussion between a 
multidisciplinary panel of NTM experts and the audience on approaches to these clinical 
situations based on available evidence and expert opinion. Challenges voiced by the 
audience and discussed with the panel included those related to: managing of newly 
acquired NTM infection, selecting and monitoring treatment regimens, determining 
treatment endpoints, and caring for patients after NTM treatment.
In the following sections, we will review challenging scenarios of people with CF and NTM 
infection in which decision making falls outside of the CFF/ECFS guidelines, and 
summarize the discussion of the expert panel and available literature.
Management of newly acquired NTM infection
Should current medications be altered?
At the time of initial NTM acquisition, one of the first considerations is whether the 
currently prescribed CF medications and treatments should be altered. For those on three 
times weekly azithromycin for immunomodulatory properties, discontinuing treatment is 
recommended once NTM is identified3 to avoid development of NTM macrolide resistance. 
The panel recommended consideration of stopping chronic inhaled tobramycin as well, to 
minimize development of NTM aminoglycoside resistance. Minimizing use of other oral 
antibiotics with activity against NTM, including linezolid, minocycline, and moxifloxacin, 
should also be considered. However, the potential benefits of discontinuation of these 
antibiotics need to be weighed against their benefits in treating other CF pathogens, as 
optimization of treatment of non-NTM CF pathogens is a critical step in the determination 
of an NTM pulmonary disease diagnosis.
How is NTM pulmonary disease diagnosed?
Another primary consideration at the time of initial NTM acquisition is whether or not NTM 
pulmonary disease is present, as this will determine whether NTM treatment should be 
considered. The CFF/ECFS and ATS/IDSA guidelines define NTM pulmonary disease 
broadly as signs and symptoms attributable to NTM infection3,4, with microbiologic and 
clinical criteria that must be fulfilled for the diagnosis of NTM disease. Certain clinical 
challenges arise in determining fulfillment of each of these criteria. Microbiologic criteria 
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for NTM disease requires at least 2 positive cultures for the same NTM species from sputum 
and/or 1 positive bronchial wash or lavage (BAL) sample3. This requirement can pose a 
challenge for patients that have difficulty expectorating sputum, and the alternative of 
bronchial wash or BAL typically requires general anesthesia in children. The panel 
discussed several approaches for obtaining AFB cultures in non-expectorating patients. The 
preferred option was induced sputum sampling, which is generally well tolerated and has a 
high rate of success in obtaining an expectorated sputum sample5,6. If NTM is suspected, but 
AFB cultures are negative, the panel recommended stopping antibiotics with activity against 
NTM for at least two weeks prior to the sample collection to increase the potential recovery 
of NTM. Finally, in the setting of M. abscessus complex infection, the clinical laboratory 
may consider performing an AFB culture on an oropharyngeal (OP) swab sample7. M. 
abscessus complex can be recovered from Burkholderia cepacia selective agar from OP 
swabs, and a positive culture with this method could contribute towards meeting 
microbiologic criteria for NTM disease. Cultures of OP swabs, however, are less sensitive 
for M. abscessus complex than cultures of sputum samples and are unlikely to detect M. 
avium complex, so a negative culture collected in this manner is not sufficient to rule out 
NTM.
Determining fulfillment of clinical criteria for NTM disease poses additional challenges. A 
chest CT is recommended at the time of a new NTM infection as part of the evaluation. 
Interpretation of the chest CT findings in regards to NTM disease is often challenging, as 
many chest-CT findings common in patients with CF (e.g., bronchiectasis, tree-in-bud) are 
not specific for NTM infection, and can represent mucus plugging or other infections. While 
it is often not possible to distinguish between NTM and CF-related chest CT findings with 
certainty, nodules, tree-in-bud, cavitary lesions, and/or subsegmental atelectasis on chest CT 
raise the index of suspicion for NTM disease, as does progression of chest CT abnormalities 
if a comparator chest CT is available8.
Does CFTR modulator therapy impact treatment decisions?
The panel discussed ways in which CFTR modulator use may factor into management of a 
newly acquired NTM infection. The impact that CFTR modulators will have on prevalence 
and outcomes of NTM infection is unclear. If a patient with new NTM infection has recently 
been started on a CFTR modulator, the panel recommended assessing the response to the 
CFTR modulator prior to diagnosing NTM pulmonary disease and initiating NTM 
treatment. In this situation, initiation of a CFTR modulator can be considered a component 
of optimizing CF treatment regimen in determining clinical criteria for NTM pulmonary 
disease. This recommendation may become more relevant with the anticipated approval of 
highly effective, triple modulator therapy. Finally, the diagnosis of NTM pulmonary disease 
is often subjective, and the decision to start NTM treatment is best made through a shared 
decision-making process with the physician and patients to weigh the risk/benefit ratios of 
whether or not to initiate NTM treatment.
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Selecting and monitoring treatment regimens
What are the preferred treatment regimens?
Once NTM pulmonary disease is diagnosed, the NTM treatment plan should be based on 
CFF/ECFS Guidelines and chosen to target the species recovered in cultures, identified to 
the subspecies level for M. abscessus complex (M abscessus subsp abscessus, M abscessus 
subsp massiliense, M abscessus subsp bolletii), and to the species level for MAC (e,g, M 
avium, M intracellulare, M. chimaera) (see guidelines for details of recommended treatment 
regimens)3. For patients with M. abscessus complex, skipping the IV intensive phase is not 
recommended. If a patient’s respiratory cultures are persistently positive for both M. 
abscessus complex and MAC, treatment for both pathogens could be considered. In this 
scenario, use of antibiotics such as azithromycin, clofazimine (if access via an 
Investiagational New Drug (IND) is available), and amikacin would be optimal as they have 
activity against both MAC and M. abscessus complex. If multiple species or subspecies 
within the same NTM complex are persistently recovered from a patient’s respiratory 
samples (e.g., co-infection with both M. abscessus and M. massiliense), the most drug-
resistant or difficult-to-treat pathogen should be targeted (e.g., target M. abscessus, in this 
example).
What about potential drug-drug interactions?
NTM treatment should be adjusted for concomitant medications that may have drug-drug 
interactions. The most notable potential drug-drug interactions in NTM treatment in CF are 
between the rifamycins and the CFTR modulator ivacaftor. Rifampin strongly induces 
metabolism of ivacaftor via cytochrome P450 making ivacaftor essentially inactive, and 
therefore should not be co-administered with CFTR modulators that contain ivacaftor9. 
Rifabutin is a moderate cytochrome P450 inducer and should also be avoided in patients on 
ivacaftor if possible. For patients on CFTR modulators that contain ivacaftor, the panel 
discussed that the preferred alternative for rifamycins when treating MAC is clofazimine via 
an IND, and inhaled amikacin as a second alternative.
What is the appropriate monitoring while on therapy?
Establishing a clear monitoring plan for side effects and drug-related toxicities prior to 
starting treatment is key to reduce potentially toxicities. Equally important is specific 
counseling and education about drug toxicity and anticipated side effects with patients. Drug 
allergy or drug intolerances, such as nausea, are common and may emerge early in the 
course of treatment. Starting drugs in a staggered fashion (e.g., several days or a week apart) 
can help to determine which drug may be the cause of a particular initial intolerance or 
reaction to allow intervention. In an effort to maximize efficacy and minimize renal toxicity, 
it is important to monitor drug levels when using intravenous aminoglycosides. Regular lab 
monitoring and clinical symptom assessment should occur and be tailored to the individual 
treatment plan3. More specific monitoring plans discussed by the panel included 
recommendations for monthly hearing exams while on intravenous aminoglycosides, as well 
as baseline and interval EKGs to monitor for a prolonged QT interval while on macrolides, 
clofazimine, and bedaquiline. Visual monitoring for color blindness while taking ethambutol 
and linezolid can be accomplished by patient self-assessment and by regular formal testing.
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How should drugs be adjusted if monitoring indicates a concern?
Adjustments to treatment regimens may be indicated due to significant drug intolerances or 
side effects, drug-drug interactions, or lack of microbiologic and/or clinical response. The 
panel suggested using 6 months after treatment initiation as a useful time point to assess 
microbiologic and clinical response and determine if changes to the treatment plan are 
indicated3. If a patient fails to convert to negative AFB cultures after 6 months of treatment, 
the panel discussed testing drug levels to ensure therapeutic dosing10, checking or repeating 
drug sensitivity testing, and considering intensification of the NTM treatment regimen.
Treatment endpoints
When does NTM treatment end?
The current standard of care in the management of NTM pulmonary disease is to continue 
therapy for 12 months beyond the date of conversion to negative cultures3. If clinical 
response has been satisfactory but treatment tolerance is an issue, the panel suggested that 
stopping NTM treatment after a minimum of 6 months of negative cultures could be 
considered. In an expectorating patient, cultures should be monitored monthly during NTM 
treatment. In a patient who is unable to expectorate sputum, home collection or sputum 
induction in clinic should be considered. Bronchoscopy with bronchial wash or BAL should 
also be considered in a patient who cannot produce sputum to ensure cultures have converted 
to negative. The panel discussed that the bronchial wash or BAL could be timed first after 3–
6 months of treatment to test for negative culture conversion, and again at the end of the 
treatment course (i.e., following 12 months of negative AFB cultures). Although less 
sensitive than AFB culture of sputum or BAL fluid, AFB culture of OP swab samples can 
also be considered for monitoring response to treatment7. However, given the lower 
sensitivity of OP swab AFB cultures, negative cultures need to be confirmed by induced 
sputum or BAL. Some centers may elect to rely on clinical and/or radiographic outcomes in 
the setting where cultures cannot be collected routinely (i.e., patients who cannot 
expectorate sputum). The panel discussed following a high-resolution chest CT every 6–12 
months during NTM treatment, including at the beginning and end of treatment. In the 
setting of cavitary disease, chest radiographs may suffice when monitoring for closure of the 
cavity. Also discussed was the option to use a low radiation dose chest CT protocol targeting 
the areas of known radiographic disease to reduce radiation exposure.
What if the patient doesn’t convert to negative cultures?
In the difficult case where all treatment strategies have been exhausted and a patient fails to 
consistently convert to negative cultures, other goals of care should be considered based on a 
shared-decision making discussion with the patient. The panel discussed the potential role 
for chronic, suppressive NTM treatment3. This could take the form of a limited NTM 
treatment regimen (e.g., a two drug regimen), but the panel strongly recommended avoiding 
monotherapy. Alternatively, one could consider scheduling planned NTM treatment periods, 
or consider intermittent NTM treatment during periods of pulmonary exacerbation or 
clinical decline, with periods off of NTM treatment in between. Alternatively, one may 
decide to stop NTM treatment and monitor closely for clinical deterioration, in which case, 
re-initiating NTM treatment may be warranted.
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Care after NTM treatment
How should patients be managed after NTM treatment?
Finally, the panel discussed clinical challenges that arise when caring for patients after 
completion of NTM treatment. For patients who have completed NTM treatment and have 
achieved negative AFB cultures, AFB cultures should be monitored at quarterly CF clinic 
visits. A common question that arises is when one could consider restarting three times 
weekly azithromycin for patients with chronic P. aeruginosa infection or with frequent 
pulmonary exacerbations. The panel, in general, preferred to not restart chronic 
azithromycin in patients who have completed NTM treatment, as risk of a subsequent NTM 
infection ranges from 24–36% within five years2. Restarting chronic azithromycin could be 
considered for select patients when the benefits of azithromycin outweigh the risk of 
macrolide resistance if a subsequent NTM infection occurred, a decision best made through 
a shared decision-making process with the patient and physician.
In conclusion, clinical challenges and areas of uncertainty exist throughout all phases of 
managing pulmonary NTM infections in people with CF. Important through all phases are a 
well-organized and closely monitored strategy that is mutually agreed upon by the provider, 
CF care team, and patient.
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Table 1:
Highlights of expert recommendations beyond CFF/ECFS guidelines.
CFF/ECSF NTM Guidelines Recommendations3 Expert Considerations Beyond the Guidelines
Stop chronic azithromycin once NTM is identified to avoid 
emergence of macrolide resistance.
Stop inhaled tobramycin to reduce risk of aminoglycoside resistance 
and minimize use of other oral antibiotics with activity against NTM.
Sputum, induced sputum, bronchial washings or bronchoalveolar 
lavage samples can be used to test for NTM.
Induced sputum is the 1st preferred alternative to expectorated sputum. 
OP swab samples plated on Burkholderia cepacia selective agar can also 
be used to recover M. abscessus complex.
All aspects of CF care should be reviewed and optimized in order to 
determine the clinical significance of NTM in the sputum.
If applicable, assess response to new CFTR modulator therapy prior to 
diagnosing NTM pulmonary disease and initiating NTM treatment.
Treatment of M. abscessus complex pulmonary disease should 
involve an intensive phase followed by a continuation phase, and 
MAC pulmonary disease should be treated with a daily oral 
antibiotic regimen containing three drugs.
Start drugs in a staggered fashion (e.g., several days or a week apart) to 
help to monitor for drug tolerance and side effects.
Use of therapeutic drug monitoring should be considered for 
individuals failing to improve despite taking recommended drug 
regimens or for those on concomitant medications with significant 
interactions with NTM drugs.
If a patient fails to convert to negative AFB cultures after 6 months of 
treatment, test drug levels to ensure therapeutic dosing, check drug 
sensitivity testing, and consider intensification of the NTM treatment 
regimen.
Individuals with CF receiving NTM treatment should have 
expectorated or induced sputum samples sent for NTM culture 
every 4–8 weeks throughout the entire course of treatment to assess 
the microbiological response.
For non-expectorating patients, a bronchial wash or BAL could be timed 
first after 3–6 months of treatment to test for negative culture 
conversion, and again at the end of the treatment course. Alternatively, 
one may rely on clinical and/or radiographic outcomes to monitor 
treatment response.
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